Kornimate/medical-research-clean huggingface dataset:
study to assess dasatinib in patients with core binding factors acute myelogenous leukemia

Conditions: Acute Myelogenous Leukemia

Summary: in patients with core binding factors acute myelogenous leukemia, the level of minimal residual disease after chemotherapy is predictive of relapse. the relapse risk is also increased in case of mutations of receptors tyrosine kinase. for patients with a high minimal residual disease level at the end of consolidation or in molecular relapse, maintenance by the inhibitor dasatinib is proposed.


Eligibility criteria:
inclusion criteria: * patient presenting de novo or secondary core binding factors acute myelogenous leukemia * patient in first and presenting one of following criteria: * "resistant" patient: decrease of less than 3 log of the acute myelogenous leukemia transcript level in the bone marrow after 2 consolidations * patient in " molecular relapse ": increase of of more than 1 log of the core acute myelogenous leukemia transcript level on two successive marrow samples exclusion criteria: * woman of childbearing potential * concurrent incurable malignacy other than acute myelogenous leukemia

Keywords: core binding factors acute myelogenous leukemia refractory to conventional chemotherapy molecular relapse
effects of photobiomodulation on insomnia in the elderly: clinical trials of phototherapy devices

Conditions: Photobiomodulation

Summary: the study will recruit 60 participants aged 60 and above, who suffered from insomnia for at least 3 months. sleep parameters and chronotypes assessed with questionnaires and actigraphy, daytime sleepiness, and biological rhythm (dim light melatonin onset) will be measured. the intervention involves light exposure using a prototype device developed by gcsol tech co., ltd., a company with expertise in light therapy research and development. three conditions will be tested (1) bright light; (2) near-infrared light; (3) bright light+ near-infrared light. data analysis will employ paired t-tests to compare sleep parameters and dim light melatonin onset before and after treatment. kruskal-wallis tests and multivariate linear regression will be used to examine differences between intervention groups, controlling for gender and age. safety analysis will include monitoring adverse events.


Eligibility criteria:
inclusion criteria: * pittsburgh sleep quality index score is 8 or above. * early wakening ( 30 minutes before expected), or interruptted sleep for more than 30 minutes, lasting for more than 3 months. exclusion criteria: * movement disorder, inability to move independently. * skin diseases, skin cancer, photosensitive skin diseases, or taking drugs that may cause photosensitivity (lithium salts, melatonin, antibiotics, a acid). * eye diseases such as glaucoma, diabetic retinopathy, and cataracts. * bipolar disorder. * light-induced epilepsy. * sleep disorders such as sleep apnea and involuntary leg twitching. * currently taking sedative-hypnotic drugs or receiving other non-drug treatments. * beck depression inventory-ii score is greater than 13 points. * those who use cardiac rhythm regulators or artificial cardiopulmonary pacemakers. * acute illness. * abnormal blood pressure or fever. * pregnancy and pregnant women. * special physical abnormalities and sensory nerve abnormalities. * infectious diseases. * coagulation disorder.

Keywords: rhythm; light therapy; insomnia; sleep; older
dentoskeletal effects of two different fixed functional appliances for correction of class ii malocclusion: a comparative clinical study

Conditions: Class II Malocclusion

Summary: fixed functional appliances comparisons in treatment of orthodontic class ii malocclusion cases

comparison between two types of fixed functional appliances, the first one is the mandibular protraction appliances, while the second one was the powerscope appliance. the treatment duration was 6 months the patients age was considered according to baccetti et al, cvmi 3,4

Eligibility criteria:
inclusion criteria: 1. skeletal and dental class ii malocclusion with mandibular retrognathia, snb\>= 4. 2. patients in cervical vertebral maturation index 3 -5. 3. age ranged from 13-16 years. 4. overjet ≥ 5 mm. 5. minimum crowding in dental arches requiring no extraction of any permanent teeth (excluding third molars). 6. good oral hygiene and general health. 7. no previous orthodontic treatment or jaw's surgery. exclusion criteria: * class i skeletal malocclusion * periodontally compromised patient * patients have systemic diseases interfering with orthodontic treatment

Keywords: powerscope mandibular protraction appliance
effectiveness of using calligraphic activity to people with schizophrenia

Conditions: Schizophrenia

Summary: to examine the effects of calligraphy activity on symptoms, attention, emotion, and quality of life in people with schizophrenia. we hypothesized that through a six-month intervention using calligraphy activity, people with schizophrenia will have their symptoms decreased, attention improved, emotion enhanced, and quality of life increased. this study will adopt single-blind, randomized controlled trial, and 160 people with schizophrenia will be recruited in this study. they will be randomly assigned to either a calligraphy activity group (treatment group; n=80) or an occupational activity group (control group; n=80). participants will complete assessments at pretest, posttest, and 3-month follow-up using the following instruments: positive and negative syndrome scale (panss), chu's attention test, the taiwanese version of montreal cognitive assessment (moca-t), who questionnaire on the quality of life, brief form (whoqol-bref), and chinese depression anxiety stress scales(dass21).


Eligibility criteria:
inclusion criteria: * inpatients * with diagnosis of schizophrenia or schizoaffective disorder * not in acute stage * voluntarily participate exclusion criteria: * severe cognition level or intellectual disability that prevent from participation * severe behavioral problems and symptoms that prevent from participation * people with blindness
does rtms induce synaptic plasticity?

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to utilize the radioactive positron emission tomography (pet) tracer \[11c\]ucb-j to investigate the effect of repetitive transcranial magnetic stimulation (rtms) on synaptic plasticity. ucb-j has been validated as a marker for synaptic density. we will use this tracer to examine if rtms leads to changes in synaptic plasticity, specifically changes in synaptic density, in individuals receiving rtms for mdd. if rtms is proven effective for increasing synaptic plasticity, there is a significant potential of a new applicable treatment for a variety of diseases that affect brain physiology.

the objective of this project is to discover the neural mechanisms by which major depressive disorder (mdd) is treated, so that we may gain insights into its pathophysiology, as well as to develop new biomarkers. we will utilize the pet tracer \[11c\]ucb-j, the first in human tracer of neural synapses, to test the hypothesis that the successful treatment of mdd with repetitive transcranial magnetic stimulation (rtms) is associated with increased synaptic density. we will use this tracer to measure synaptic density before and after rtms treatment and compare change in synaptic density between subjects who respond to the rtms treatment and those who do not respond to treatment. the finding of a marked increase in synaptic density in participants who respond to rtms treatment would point to the possibility of developing new treatments with the potential to modify disease through mitigating, preventing or remediating synaptic loss.

Eligibility criteria:
inclusion criteria: * 18-70 years in age * u.s. veteran * diagnosis of mdd * on a stable medication regimen for at least two weeks prior to testing * stable social environment and housing to enable regular attendance at clinic visits * ability to undergo cognitive testing, clinical assessments, and pet/mr scans * stable medical health * will undergo rtms treatment for mdd at the va palo alto * able to complete a pet-mr scan without the use of sedation exclusion criteria: * active substance use within three months of testing * iq \< 70 * major medical neurological illness or significant head trauma * pregnancy or breastfeeding * contraindication to mr scanning, including magnetic-resonance incompatible metal or hardware including pacemakers, cochlear implants, and bullets near a critical organ * weight \> 350 lbs or a large body habitus that mr scanner cannot accommodate * history of or current claustrophobia * inability to comply with basic study requirements such as following directions and punctuality * acute or unstable chronic medical illness that would affect participation or compliance with study procedures, e.g. unstable angina * unstable psychiatric symptoms that precludes consistent participation in the study, e.g. active current suicidal intent or plan, severe psychosis * inability to undergo pet/mr scan, e.g. claustrophobia, presence of ferromagnetic objects in subject's body
etanercept (enbrel®) in psoriasis - pediatrics

Conditions: Psoriasis

Summary: this study will evaluate the safety and efficacy of etanercept (enbrel®) in children with psoriasis.

on enrollment, participants underwent randomization in a 1:1 ratio to receive placebo or etanercept during the initial double-blind period. participants could enter an escape group and receive open-label etanercept until week 12 if, at or after week 4, their psoriasis area and severity index (pasi) score either increased by more than 50% over baseline and by a minimum of 4 points at one visit or increased by more than 25% and by a minimum of 4 points at each of two consecutive visits. during the open-label treatment period, all patients (including those who entered the escape group) received open-label etanercept. participants who did not achieve pasi 50 at week 24 or pasi 75 at week 36 could discontinue the study or add topical standard-of-care therapy (low-to-moderate-potency topical corticosteroids) and continue to receive open-label etanercept until week 48. at week 36, participants with pasi 50 at week 24 or pasi 75 at week 36 were randomly assigned to placebo or etanercept for 12 weeks in the withdrawal period. participants in whom pasi 75 was lost resumed open-label etanercept through week 48 in the re-treatment period.

Eligibility criteria:
* patients with plaque psoriasis * patient may not receive certain psoriasis medications during the study

Keywords: pediatric psoriasis
effects of hand motor rehabilitation using a semg-biofeedback

Conditions: Stroke; Stroke, Ischemic; Stroke Hemorrhagic; Hemiparesis

Summary: stroke is the first cause of disability worldwide. the motor impairment of the hand is one of the most common sequelae in patients after stroke. indeed, approximately 60% of patients with diagnosis of stroke suffers from hand sensorimotor impairment. in the last years, new approaches in neurorehabilitation field has been permitted to enhance hand motor recovery. wearable devices permit to apply sensors to the patient's body for monitoring the kinematic and dynamic characteristics of patient's motion. moreover, wearable sensors combined with electrodes detecting muscle activation (i.e. surface electromyography - semg) permit to provide biofeedback to the patient to improve motor recovery.

the aim of the study is to investigate the effect of using remo® (morecognition srl, turin, italy) device in hand motor rehabilitation. the device remo® is an armband composed by 8 bipolar electrodes able to record and process the electromyography of forearm muscles. the patterns of muscle activations are classified and used to perform semg-biofeedback exercises in stroke rehabilitation training. the device is developed by clinicians of irccs san camillo hospital and morecognition srl. a total of 20 patients with first diagnosis of stroke and with no other neurological diagnosis or severe cognitive impairment has been enrolled. the patients are tested with remo® and if they are able to control at least one movements, they are enrolled in the longitudinal pilot study. the treatment consists in 15 sessions, 1hour/day, for 5 days/week, for 3 weeks. the patients are clinically evaluated before and after the remo® treatment to define clinical effect of the semg-biofeedback training.

Eligibility criteria:
inclusion criteria: * single ischemic or haemorrhagic stroke * able to control at least 1 movement with remo (i.e. able to cross the pre-defined empirical threshold (10%) of the ratio between the maximum voluntary contraction (mvc) of the movement and the emg recording during baseline (i.e. rest position) exclusion criteria: * untreated epilepsy; * major depressive disorder; * fractures; * traumatic brain injury; * severe ideomotor apraxia; * severe neglect; * severe impairment of verbal comprehension.

Keywords: neurological rehabilitation hand recovery electromyography
single infusion of liposomal amphotericin b in indian visceral leishmaniasis

Conditions: Visceral Leishmaniasis

Summary: the purpose of this trial is to evaluate the efficacy of single dose amphotericin b in the treatment of visceral leishmaniasis (vl) in india.

the purpose of this trial is to evaluate the efficacy of single dose amphotericin b in the treatment of vl in india. primary objective: comparison of the efficacy of single dose of 10 mg/kg of liposomal amphotericin b to amphotericin b deoxycholate with regards to final cure rates secondary objective:. comparison of the safety of single dose of 10 mg/kg of liposomal amphotericin b to amphotericin b deoxycholate when administered in the proposed dosage regimens.

Eligibility criteria:
inclusion criteria: * children and adults 2-65 years of age (inclusive) of either gender. * diagnosis of vl confirmed by spleen or bone marrow aspirate. * clinical signs and symptoms compatible with vl. * biochemical and haematological test values as follows: * haemoglobin \> 3.5g/100ml * white blood cell count \> 0.75 x109/l * platelet count \> 40 x 109/l * ast, alt and alkaline phosphatase \< 5 times upper normal limit * prothrombin time \< 4 seconds above control * serum creatinine levels - 1.5 times upper normal limit * serum potassium levels within normal limits * hiv negative. exclusion criteria: * a history of intercurrent or concurrent diseases (e.g. chronic alcohol consumption or drug addiction; renal, hepatic, cardiovascular or cns disease; diabetes; tuberculosis; other infectious or major psychiatric diseases) that may introduce variables that affect the outcome of the study. * any condition which the investigator thinks may prevent the patient from completing the study therapy and subsequent follow-up. * proteinuria (\> 2+). * a history of allergy or hypersensitivity to amphotericin b * previous treatment for vl within two weeks of enrollment into the study. * prior treatment failures with amphotericin b.

Keywords: visceral leishmaniasis india liposomal amphotericin b amphotericin b deoxycholate
simultaneous application of ketamine and lidocaine during an ambulatory infusion therapy as a treatment option in refractory chronic pain conditions

Conditions: Chronic Pain

Summary: this study is to retrospective investigate the effects of the simultaneous intravenous (i.v.) administration of lidocaine and ketamine on a four to six weeks interval in treatment refractory different chronic pain conditions.

the use of intravenous infusion therapy with lidocaine or ketamine has been of interest in several chronic pain conditions. studies showed a benefit in immediate pain reduction and even longer lasting pain relief for treatment approaches with lidocaine and ketamine. while there is a broad database on the use of lidocaine and ketamine in chronic pain management as separate agents, very few pre-clinical animal studies have investigated the combined use of said analgesics and none of them reports their combined use in chronic pain patients. this study is to retrospective investigate the effects of the simultaneous i.v. administration of lidocaine and ketamine on a four to six weeks interval in treatment refractory different chronic pain conditions.

Eligibility criteria:
inclusion criteria: * icd11 medical diagnosis of chronic pain and its subcategories * treatment with intravenous lidocaine and ketamine infusions during the years of 2012 to may 2021 at our pain unit at the usb * patient is at least 18 years of age at the beginning of the first infusion treatment exclusion criteria: * patient is underage at the beginning of the first infusion treatment * documented written refusal of consent for research (general consent or specific study consent) * patients undergoing treatment with only lidocaine or ketamine respective

Keywords: lidocaine ketamine
nasm opt for pectoral enhancement and breast firmness in non-athletic women: an rct

Conditions: Low Back Pain; Muscle Weakness; Breast Sagging

Summary: this rct investigates a 12-week nasm opt program targeting pectoral muscle strength, breast aesthetics (firmness, lift, chest circumference), and low back pain in 120 non-athletic women. the intervention group performed structured resistance training, while the control group engaged in general exercise. outcomes included pectoral strength (dynamometer), aesthetic satisfaction (likert scale), and functional performance (push-up test).

participants were randomized to nasm opt (3 weekly sessions: stabilization, strength, and hypertrophy phases) or general exercise (brisk walking/aerobics). measurements at baseline and 12 weeks included pectoral strength, chest circumference, low back pain (vas), and perceived breast aesthetics.

Eligibility criteria:
inclusion criteria: * non-athletic women (no exercise in prior 6 months). * interest in improving chest aesthetics. * no musculoskeletal injuries. exclusion criteria: * pregnancy * chronic illness * exercise contraindications

Keywords: nasm opt pectoral muscles breast firmness non-athletic women resistance training
measles, mumps, and rubella (mmr) immunity in college students

Conditions: Measles; Mumps; Rubella

Summary: this study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the mid west, and it will assess the potential for similar outbreaks of measles and rubella. a total of 70 to 80 college students (age 18 to 22) on the emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. their medical records will be verified for documentation of immunization with mmr vaccine prior to enrollment in the study. if a study volunteer is found to not have mmr immunity, they will be offered an mmr-ii vaccine. for this group, additional blood specimens will be obtained.

no additional description needed.

Eligibility criteria:
inclusion criteria: * ability and willing to provide an informed consent * documented receipt of mmr-ii vaccination in childhood * not pregnant exclusion criteria * no history of hiv infection. * immunocompromised health status due to hiv infection, cancer, diabetes, liver, lung or kidney diseases, autoimmune diseases, history of splenectomy. * use of immunosuppressive medications within last 2 to 3 months (oral or parenteral corticosteroids or cytotoxic medications) * medical conditions that require the use of immunosuppressive medications * received blood or blood products within the last 30 days * any vaccines received in the last 30 days

Keywords: mumps immunity vaccine mumps antibodies mumps immunity
platelet dysfunction in blood donors

Conditions: Platelet Dysfunction in Blood Donors

Summary: platelets are circulating blood cells. they bind to each other and to the damaged vessel wall to prevent excessive bllod loss. unlike quantitative platelet defects, there is no automated, simple test to diagnose qualitative platelets defects. however, these defects expose to bleeding in a surgical situation and could explain the transfusion inefficiency of some platelet concentrates. in recent decades, considerable progress has been made in understanding qualitative platelet disorders. in this project, we propose to submit blood donors to a standardized hemorrhagic diathesis questionnaire and to compare the prevalence of platelet function abnormalities in blood donors with and without hemorrhagic diathesis.

primary objective specify the prevalence of qualitative platelet disorders in blood donors with i) a clinical history of bleeding diathesis collected through a standardized and validated questionnaire ii) and / or a hematoma (more than 4 cm) that occurred during blood donation. secondary objectives to obtain the prevalence of other defects of hemostasis

Eligibility criteria:
inclusion criteria: - any male or female volunteer eligible for the blood donation exclusion criteria: * subject with contraindications to blood donation: * weight \<50 kg; * severe fatigue, * anemia, * insulin-dependent diabetes; * subject treated for epileptic seizures or having followed a treatment whose arrest is less than 14 days old. * active pregnancy or childbirth less than 6 months old. * viral disease (eg influenza, gastroenteritis ...) active less than two weeks after the end of symptoms. * waiting period not respected after certain acts of daily life according to the regulatory criteria set by the efs * hiv infection, hepatitis b, hepatitis c

Keywords: platelets bleeding
parkinsonism-related oscillations in the cortico-basal ganglia-thalamic network during movement: beyond the frequency range

Conditions: Parkinson Disease; Hyperkinesis; Hypokinesia

Summary: expression of hypokinetic and hyperkinetic motor symptoms in parkinson's disease (pd) is associated with pathological synchronous oscillations of neuronal activity (local field potential/lfp) in the cortico-subcortical network with a wide frequency range. in the present project, we propose to study cortico-subcortical oscillations and their synchronization in patients operated for pd (subthalamic deep brain stimulation (stn-dbs)) during distinct pharmacological and stimulation conditions (hypokinetic and hyperkinetic), using a simple motor task.

to define the link between the characteristics of neuronal oscillations (frequency, amplitude, phase relationship) within the cortico-subcortical network and the movement, we designed a simple motor task of gripping/pulling a lever. the lfps will be collected at the cortical and subcortical levels (stn) during the motor task using a high-resolution eeg (hr-eeg) and the percept™ system (medtronic). recordings will be realized in four conditions: without pharmacological treatment and without stimulation (off condition), without pharmacological treatment and during stimulation (dbs condition), during pharmacological treatment and without stimulation (dopa condition) and during pharmacological treatment and stimulation (dopa+dbs condition).

Eligibility criteria:
inclusion criteria: * male or female * 18 to 75 years-old * with idiopathic parkinson's disease * having a stn-dbs with a percept™ for less than a year or being candidate for stn-dbs with the percept™ device (first-implantation) * able to perform the simple motor task * patients covered by a health insurance scheme * giving free, informed, written consent signed by the participant and the investigator. exclusion criteria: * be incapable of giving consent personally. * be subject to a legal protection measure (curatorship, guardianship) or be placed under judicial protection. * being pregnant or breastfeeding * present a serious and/or decompensated somatic or psychiatric illness.

Keywords: parkinson disease hypokinetic disorders dyskinesia networks basal ganglia